January 2024

Implementation of Regulatory Guidance for JAK Inhibitors Use in Patients with Immune-Mediated Inflammatory Diseases: An International Appropriateness Study

Autoimmun Rev. 2023;23(3):103504 doi: 10.1016/j.autrev.2023.103504 Epub ahead of print

In this two-round modified RAM study by Solitano, et al., the authors found that experts preferred to assess JAK inhibitor risk on a case-by-case basis across all specialties. Uncertainty remained on several clinical scenarios regarding the appropriate use of JAK inhibitors, however they remain an important therapy option for the treatment of IMIDs  and were deemed appropriate for patients with moderate risk profiles.

Keywords:

Drug Survival, Effectiveness and Safety of Ixekizumab for Moderate-to-severe Psoriasis up to 5 Years

J Eur Acad Dermatol Venereol 2024;8(1):3 doi 10.1111/jdv.19682

This monocentric, retrospective clinical study by Mastorino, et al. found that ixekizumab demonstrated efficacy an safety in patients with PsA and PsO for up to five years. Being a super-responder was significantly associated with a lower rate of discontinuation, while high BMI was associated with a lower achievement of more than one PSAI measure up to Week 104.

Keywords:

December 2023

Efficacité et sécurité comparatives du bimekizumab dans la spondyloarthrite axiale : Une revue systématique de la littérature et une méta-analyse en réseau

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead598 Epub ahead of print

This systematic literature review and network meta-analysis provides evidence for bimekizumab being an efficacious option in the management of both b/tsDMARD-naïve and experienced patients across the axSpA spectrum, with similar safety and tolerability to existing treatments.

Keywords:

Étude comparative en situation réelle de l'efficacité des inhibiteurs de Janus Kinase chez les patients atteints de polyarthrite rhumatoïde : L'étude de cohorte ANSWER

Rheumatology 2023 doi 10.1093/rheumatology/kead543

This multicentre, retrospective study by Hayashi, et al. found no significant differences in efficacy and safety between tofacitinib, baricitinib, peficitinib and upadacitinib in patients with RA. Predictive factors for resistance to LDA achievement included baseline CRP and CDAI for tofacitinib and baseline glucocorticoid dose, baseline CDAI and number of previous b/tsDMARDs for baricitinib.

Keywords:

Différences liées au sexe dans les caractéristiques des patients et dans l'efficacité et la sécurité des thérapies avancées dans les essais cliniques randomisés sur le rhumatisme psoriasique : Une revue systématique de la littérature et une méta-analyse

Lancet Rheumatol 2023;5:e716–27

In this study, Eder, et al. performed a systematic literature review and meta-analysis of RCTs to assess information on participants’ characteristics and rates of American College of Rheumatology response and minimal disease activity by sex. The authors found that the biological sex of patients with PsA influences their response to advanced therapies, but the effect varies by drug class.

Keywords:

November 2023

Efficacité et sécurité du tofacitinib chez les patients atteints de spondylarthrite ankylosante en fonction de la prise antérieure d'antirhumatismaux modificateurs de la maladie : Une analyse post hoc

ACR Open Rheumatol. 2023;5(12)632–643 doi 10.1002/acr2.11601

In this post hoc analysis by Deoodhar, et al., the authors found that tofacitinib demonstrated greater efficacy than placebo in bDMARD-naïve and TNFi-IR AS patients. They also found that safety event rates for tofacitinib therapy were numerically higher in the TNFi-IR subgroup than the bDMARD-naïve subgroup.

Keywords:

Traitement au bimékizumab chez les patients atteints de spondylarthrite axiale active: efficacité et innocuité à 52 semaines des études randomisées et parallèles de phase 3 BE MOBILE 1 et BE MOBILE 2

Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803

Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.

Keywords:

Différences spécifiques liées au genre chez les patients atteints de rhumatisme psoriasique recevant de l'ustekinumab ou un inhibiteur du facteur de nécrose tumorale : Données en situation réelle

Rheumatology (Oxford) doi:10.1093/rheumatology/kead089.

Real-world data from the PsABio study indicated that females with PsA had more severe disease than males before the initiation of treatment. While both genders experienced treatment related improvements, fewer females than males were able to achieve a favourable disease state within 12 months. Treatment discontinuation and switching were also higher in females than males, due to lower efficacy and adverse events.      

Keywords:

Sécurité à long terme du guselkumab chez les patients atteints de maladie psoriasique : Analyse intégrée de onze études cliniques de phase II/III sur le psoriasis et le rhumatisme psoriasique

Drug Saf 2023;47(1)39–57 doi:10.1007/s40264-023-01361-w

Data gathered from 11 phase 2 and phase 3 trials have shown that guselkumab has a favourable safety profile in treating psoriatic disease. The data were gathered from 4399 patients over 10787 patient years. In the placebo-controlled periods, guselkumab showed a similar safety profile to placebo, and this remained consistent and stable in the non-placebo controlled preiods.

Keywords:

October 2023

Une étude d'efficacité en situation réelle utilisant une application mobile pour évaluer les résultats précoces de l'Upadacitinib dans la polyarthrite rhumatoïde

Rheumatol Ther. 2023;10(6):1519–1533 doi 10.1007/s40744-023-00594-6

This study by Harrold, et al. showed that RA patients initiating upadacitinib reported improvements in RAPID3, pain, stiffness, and fatigue as early as Week 1, with 37.5% achieving RAPID3 LDA at Week 12. TNFi-experienced patients had similar outcomes.

Keywords: